Aarey DRUGS & PHARMACEUTICALS LTD.

MANUFACTURER OF BULK DRUGS & IMPORTERS OF SOLVENTS & CHEMICALS

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ✆ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ✆ (02525) 271049 Email: info@aareydrugs.com
CIN:L99999MH1990PLC056538

Date: 14th August, 2026

To,

BSE Limited	**National Stock Exchange of India Limited**
The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001 **Scrip Code: 524412**	Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai – 400051 **NSE Symbol: AAREYDRUGS**

Sub: Outcome of Board Meeting held on today i.e 14th August, 2026

Dear Sir/Madam,

This is to inform you that a meeting of the board of directors of the company was held today i.e. on Friday, 14th August, 2026 at the registered office of the company, inter alia, to consider and take on record the Unaudited Financial Results (on standalone basis) of the company for the first quarter ended on 30th June, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and basis recommendation of the Audit Committee has, inter alia, approved the following.

1. The Board of Directors of the Company has considered and approved the Unaudited Financial Results for the quarter ended 30th June, 2026 along with the Limited Review Report, MD/CFO certification.

2. Statement of Deviation or Variation in Utilization of Funds Raised through Convertible Warrants (Preferential Issue).

   *Company segment is single

Kindly find attached herewith a copy of the Unaudited standalone financial results along with Limited Review Report of the company for the first quarter ended on 30th June, 2026 and Statement of Deviation or Variation.

Further, please note that in terms of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window of the Company will be open after 48 hours after the announcement of the said results.

The meeting was started at 05:00 p.m. and was concluded at 07:00 p.m

Kindly take the same on record.

Thanking you,

Yours Faithfully,

For AAREY DRUGS & PHARMACEUTICALS LIMITED

Nimit Rajesh Ghatalia
Digitally signed by Nimit Rajesh Ghatalia
Date: 2026.08.14 19:54:59 +05'30'

Nimit R Ghatalia
Director
DIN: 07069841

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended

Review Report to,
The Board of Directors
Aarey Drugs and Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Aarey Drugs and Pharmaceuticals Limited** ("the Company") for the quarter ended June 30, 2026 and year to date from April 01, 2026 to June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the listing Regulations").

2. The Company's management is responsible for preparation of the statement in the accordance with the recognition and measurement and principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim financial reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Director. Our responsibility is to express conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

MOTILAL & ASSOCIATES LLP
106584W/
W1
CHARTERED ACCOUNTANT

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Motilal & Associates LLP
(a member firm of M A R C K S Network)
Chartered Accountants
ICAI FRN: 106584W/W100751

MOTILAL & ASSOCIATES LLP
106584W/
W100751
CHARTERED ACCOUNTANT

Motilal Jain
Partner
ICAI MRN: 036811
Place: Mumbai

Date: 14th August, 2026
UDIN: **26036811GOVODO3820**

AAREY DRUGS & PHARMACEUTICALS LTD
CIN: L99999MH1990PLC056538
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30TH JUNE, 2026
(Rs. In Lakhs except EPS)

Particulars	Quarter ended			Year Ended
	30.06.2026 (Unaudited)	31.03.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
Revenue from Operations	4462.55	18,947.24	10,220.83	47,226.90
Other Income	171.50	(42.94)	155.18	609.71
TOTAL INCOME	**4634.05**	**18,904.29**	**10,376.00**	**47,836.61**
EXPENSES				
Cost of Materials Consumed	4347.76	17,929.60	9,306.79	45,056.29
Changes in Inventories of Finished goods, Work in progress and Stock in trade	(132.35)	9.61	476.78	394.41
Employee Benefit Expenses	16.34	28.97	13.84	75.90
General Administrative expense	17.95	24.09	16.95	92.81
Selling and Distribution Expense	34.62	339.09	39.89	397.46
Finance Cost	167.44	178.47	103.76	500.18
Depreciation and Amortization Expense	85.02	84.64	48.83	285.30
Other Expenses	45.70	181.83	196.33	492.84
TOTAL EXPENSES	**4,582.49**	**18,776.29**	**10,203.18**	**47,295.19**
Profit Before Exceptional Items and Tax	**51.56**	**128.01**	**172.82**	**541.42**
Exceptional Items	-	-	-	-
Profit / (Loss) Before Tax	**51.56**	**128.01**	**172.82**	**541.42**
Tax Expenses	**(50.81)**	**27.74**	**35.69**	**144.66**
a) Short/(excess) provision of earlier years	-	-	-	-
b) Current Tax	30.00	51.76	35.00	159.25
c) Deferred Tax	(80.81)	(24.03)	0.69	(14.59)
Profit / (Loss) for the period from continuing operations	**102.37**	**100.27**	**137.13**	**396.76**
Profit/(loss) from discontinued operations	-	-	-	-
Tax expense of discontinued operations	-	-	-	-
Profit/(loss) from Discontinued operations (after tax)	-	-	-	-
Profit/(loss) for the period	**102.37**	**100.27**	**137.13**	**396.76**
Other Comprehensive Income	-	-	-	

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI *

Total Comprehensive Income for the year	**102.37**	**100.27**	**137.13**	**396.76**
Earnings per equity share : (of Rs. 10/- each) (for the period/year): *				
a) Basic EPS (Rs.)	0.36	0.35	0.48	1.39
b) Diluted EPS (Rs.)	0.36	0.35	0.48	1.39
Number of Shares	28,454,303	28,454,303	28,454,303	28,454,303
Percentage of Shareholding	100%	100%	100%	100%
Paid-up Equity Share Capital (FV of Rs. 10/- each) (incl. forfeited shares)	2,845.43	2,845.43	2,845.43	2,845.43

***Not Annualised**

1. The above unaudited Financial results of the Company for the quarter ended 30th June, 2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors at their respective meetings held on 14th August,2026.

2. The aforesaid unaudited Financial results for the quarter ended 30th June, 2026 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under Secüon 133 of the Comparúes Act, 2013 read with the relavant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of SEBI (Listing, Obligation and disclosure Requirements) Relations, 2015.

3. The Company operates only in one segment in Manufacturing and Trading of Drugs & Pharmaceutical and all other allied activities revolving around the same. As such there is no other separate reportable segment as defined by IND AS 108 -"Operating Segments"

4. The Figures of the previous year and/or period(s) have been regrouped wherever necessary.

By Order of the Board of Directors
For Aarey Drugs and Pharmaceuticals Limited

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Mihir R Ghatalia
Managing Director
DIN: 00581005

Date: 14th August,2026
Place: Mumbai

MANUFATURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS

Aarey

DRUGS & PHARMACEUTICALS LTD.

GST NO. : 27AAACA5253A1Z9
CIN NO. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA, TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C., TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL.: (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Certificate of Managing Director (MD)

I, Mihir R. Ghatalia, Managing Director (MD) of Aarey Drugs & Pharmaceuticals Ltd., certify;

1) That I have reviewed the Unaudited Financial Statements for the quarter ended 30th June, 2026 and to the best of my knowledge and belief:

a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and

b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.

2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.

3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Mihir R. Ghatalia
MD
Date: 14/08/2026
Place: Mumbai

MANUFATURERS OF BULK DRUGS &
DEALERS OF CHEMICAL & SOLVENTS

Aarey
DRUGS & PHARMACEUTICALS LTD.

GST NO. : 27AAACA5253A1Z9
CIN NO. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA, TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com
REGD. OFFICE & FACTORY : E-34, M.I.D.C., TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL.: (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Certificate of Chief Financial Officer (CFO)

I, Mira R. Ghatalia, Chief Financial Officer (CFO) of Aarey Drugs & Pharmaceuticals Ltd., certify;

1) That I have reviewed the Unaudited Financial Statements for the quarter ended 30th June, 2026 and to the best of my knowledge and belief:

a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and

b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.

2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.

3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Mira M.Ghatalia
CFO
Date: 14/08/2026
Place: Mumbai

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ✆ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ✆ (02525) 271049 Email: info@aareydrugs.com
CIN:L99999MH1990PLC056538

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTSISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Statement on deviation / variation in utilisation of funds raised	
Name of Listed Entity	Aarey Drugs & Pharmaceuticals Limited
Mode of Fund Raising ((Public Issues / Rights Issues / Preferential Issues / QIP / Others)	Convertible Warrants_Preferential Basis ("Preferential Issue")
Date of Raising Funds	23/5/2025 (Date of Allotment)
Amount Raised	Rs.797.50 lakhs
Report filed for Quarter ended	30-06-2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	Not Applicable
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	Nil
Objects for which funds have been raised and where there has been a deviation, in the following table	-

Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any (Revised Allocation)	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
The Company, as a part of its financial strategy, proposes to offer, issue and allot Convertible Warrants to its Promoter/Non-Promoter/Promoter group member on preferential basis, for infusing additional	Nil	3,190.00	Nil	Nil	Nil	The Company had allotted 50,00,000 Convertible Warrants on May 23, 2025, at an issue price of Rs. 63.80 per warrant, aggregating to Rs. 3,190.00 lakhs. In accordance with

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ✆ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ✆ (02525) 271049 Email: info@aareydrugs.com
CIN:L99999MH1990PLC056538

funds in the Company which may be employed in the business of the Company and/or may be used to augment the funding needs for re-structuring/settlement of liabilities/debts and/or such other appropriate arrangements and/or understanding with Bankers and/or other Creditors and/or investment in technology and/or for general corporate purposes which shall enhance the business of the Company and for any other purpose as may be decided and approved by the Board.						the SEBI (ICDR) Regulations, 25% of the consideration amounting to Rs. 797.50 lakhs was received at the time of allotment and was utilized for the stated objects. The balance 75% consideration amounting to Rs. 2,392.50 lakhs is receivable upon exercise/conversion of the warrants within the prescribed period. The aforesaid details were reported in the Statement of Deviation and Variation for the year ended March 31, 2026. During the quarter ended June 30, 2026, no further funds were received towards the balance consideration of the Convertible Warrants. Accordingly, there was no fresh fund receipt or utilization during the quarter and the Statement of Deviation and Variation for the quarter ended June 30, 2026 has been filed as **Nil**.

H.O: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ✆ : (022) 23455543 Email: corporate@aareydrugs.com
REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ✆ (02525) 271049 Email: info@aareydrugs.com
CIN:L99999MH1990PLC056538

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

Note:
No funds were received during the quarter ended June 30, 2026. Accordingly, there was no deviation or variation in the utilization of funds during the quarter and the Statement is filed as Nil.

For on Behalf of Board
Aarey Drugs & Pharmaceuticals Limited

AAREY DRUGS & PHARMACEUTICALS LTD. MUMBAI

Mira M.Ghatalia
CFO